Dyadic International, Inc.
Dyadic International, Inc.
Dyadic International, Inc.
DYAI
DYAI
Nasdaq
Health Services
Medical/Nursing Services
1.19
USD
-0.02
-1.65%
Closed: 07-24 20:00 (UTC+0)
1.19
USD
+0.0559
+4.70%
After Hours: 07-25 00:00 (UTC+0)

DYAI Key Statistics

High
1.26
Open
1.21
Volume
105.18K
Low
1.12
Prev. Close
1.21
Trading Value
125.54K
52-Week High
1.60
Relative Volume
0.371
Amplitude (%)
11.49%
52-Week Low
0.65
Turnover Rate
0.29%
Market Cap
43.36M
P/E Ratio (TTM)
--
P/E Ratio (Annual)
--
P/B Ratio
-106.35
P/S Ratio
11.39
Earnings Per Share (EPS)
-0.214
Dividend (TTM)
0
Dividend Yield
0.00%
Shares Outstanding
36.43M
Currency Unit
USD

DYAI Price Performance

7 day
30 day
90 day
180 day
Year to date
1 Year
DYAI Money Flow Distribution
DYAI Daily Short Sale Volume
DYAI Short Interest History
As of 2026-07-26, the Dyadic International, Inc. (DYAI) stock price today is 1.19. Based on this price, the company has a market capitalization of $43.36M, with a P/E ratio of --. On 2026-07-26, DYAI traded between 1.12 and 1.26. Today’s stock price is 6.25% above the daily low and 5.56% below the daily high, placing DYAI near the middle of its most recent trading range. Trading volume currently stands at 105.18K, compared with an average daily volume of 283.91K. This suggests that trading activity is significantly below its usual level than usual. Over the past year, Dyadic International, Inc. shares have traded between 0.65 and 1.60. At today’s price, DYAI is 83.08% above its 52-week low and 25.63% below its 52-week high.
Company Name
Dyadic International, Inc.
Sector
Health Services
Industry
Medical/Nursing Services
Exchanges
Nasdaq
Number of Employees
5
Lot Size
100
Official Website
Currency Unit
USD
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

DYAI FAQ